Congress Can Fix the Dangerous Dependence on Imported Pharmaceuticals
In the wake of the COVID pandemic, consumers have become painfully aware of America’s heavy dependence on imports. The recent Amoxicillin shortage in hospitals has
Loophole in U.S. Customs Law Contributing to Fentanyl Deaths
Last year, more than 73,000 Americans died from an overdose of the synthetic opioid fentanyl. The drug itself is cheap and readily available, with thousands of pounds flowing into
Senators Demand Clarity On Imports In New Bill, Seeking Consumer Protection & Better Trade Rules Enforcement
Manifest Modernization Act would require companies like FedEx and DHL, which import goods into the U.S., to follow same rules as ocean shipping companies. The bill was written by Sens. Cassidy and Whitehouse.
Sens. Manchin, Barrasso Sound Alarm On IRA Failings Related To EVs, Natural Resources
The leaders of the Senate Energy and Natural Resources Committee grilled a government official on the EV batteries supply chain. From copper to EV battery minerals, the U.S. is way behind.
If Companies Are Leaving China, Where Are They Going, And Why?
Dan Harris, international lawyer at Harris Bricken and founding author of the China Law Blog talks about companies leaving China. Are any coming here?
For Some, Leaving China Does Not Mean Leaving Chinese Businesses
Companies are leaving China for Southeast Asia, but in many cases, that doesn’t mean they have stopped doing business with the same Chinese company.
Government Incentives Needed To Reshore Critical Supply Chains, From Pharmaceuticals to Minerals
The U.S. China Economic & Security Review Commission heard from witnesses about keeping auto tariffs on China, and more incentives for manufacturing to reshore.
Supply Chain Crisis, Not Tariffs, Stoked Inflation
Don’t blame the China tariffs on inflation. Supply chain snafus were a much bigger deal, a Federal Reserve report says.
Katherine Tai Says Globalization No Longer Sustainable
At National Press Club, Katherine Tai talks about supply chain issues, what ‘de-risking’ from China might look like, and how USTR thinks about it.
FDA Allows Uninspected China Lab to Sell Cancer Drugs in the US
A Chinese cancer drug maker that has not been inspected by the FDA since 2018 is selling chemotherapy drugs to the U.S. due to shortages. When will the U.S. meet its critical medication needs?
